Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome

A Barry Kay; Amy D Klion

doi:10.1016/j.iac.2004.06.007

Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome

Immunol Allergy Clin North Am. 2004 Nov;24(4):645-66, vii. doi: 10.1016/j.iac.2004.06.007.

Authors

A Barry Kay¹, Amy D Klion

Affiliation

¹ Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Guy Scadding Building, Dovehouse Street, London, SW3 6LY UK. a.b.kay@imperial.ac.uk

PMID: 15474864
DOI: 10.1016/j.iac.2004.06.007

Abstract

Interleukin 5 (IL-5) is a key cytokine in the regulation of eosinophilia and eosinophil activation in humans. Monoclonal antibodies to anti-IL-5 have become available for use in clinical studies in humans. This article discusses the rationale for the use of anti-IL-5 therapy in asthma and hypereosinophilic syndrome and summarizes the available clinical data on the use of anti-IL-5 to treat these disorders.

Publication types

Review

MeSH terms

Asthma / drug therapy*
Asthma / etiology
Eosinophils / physiology
Extracellular Matrix Proteins / genetics
Humans
Hypereosinophilic Syndrome / drug therapy*
Interleukin-5 / antagonists & inhibitors*
Interleukin-5 / physiology
RNA, Messenger / analysis
Transforming Growth Factor beta / genetics
Transforming Growth Factor beta1

Substances

Extracellular Matrix Proteins
Interleukin-5
RNA, Messenger
TGFB1 protein, human
Transforming Growth Factor beta
Transforming Growth Factor beta1